Asia Pacific Breast Cancer Screening Market Forecast to 2027
Bharat Book Bureau Provides the Trending Market Research Report on “Asia Pacific Breast Cancer Screening Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Test Type (Blood Marker Test, Imaging Test, Genetic Test, Immunohistochemistry Test),End User (Hospitals, Diagnostic Centers, Cancer Institutes, Research Laboratories), and Country�under Healthcare Category. The report offers a collection of superior market research, market analysis, competitive intelligence and Market reports. The Asia Pacific Breast Cancer Screening Market was valued at US$ 798.57 million in 2019 and is projected to reach US$ 1,120.77 million by 2027; it is expected to grow at CAGR of 5.4% from 2020 to 2027. Driving factors such as, increasing investments for research in breast cancer management and growing breast cancer prevalence across Asia Pacific are expected to propel the growth of the market during the forecast period. However, high cost associated with breast cancer screening is likely to pose a negative impact on the market growth. Growing prevalence of cancer in china is likely to demand breast cancer screening technology. As per the Globocan report, in 2018, there were around 367,900 new cases of breast cancer and 97,972 deaths due to breast cancer in china. Furthermore, increasing prevalence of breast cancer in Japan is likely to demand the breast cancer screening test in Japan. This is expected to drive market growth in Japan. As per Globocan in 2018, Japan had around 66,101 new cases of breast cancer and 15,452 breast cancer deaths. Additionally, In India, as per the Globocan report, in 2018 there were around 1,62,468 new breast cancer cases and 87,090 breast cancer deaths.